Silence slows phase 3 plans for cardio drug, as Hansoh opts out of $1.3B biobucks collab
“While we remain confident in our zerlasiran program for high Lp(a), we will only initiate the phase 3 cardiovascular outcomes study once a partner is secured,” Silence CEO Craig Tooman said.
“While we remain confident in our zerlasiran program for high Lp(a), we will only initiate the phase 3 cardiovascular outcomes study once a partner is secured,” Silence CEO Craig Tooman said.
